D. Johnston

6.6k total citations · 1 hit paper
23 papers, 5.1k citations indexed

About

D. Johnston is a scholar working on Oncology, Surgery and Hematology. According to data from OpenAlex, D. Johnston has authored 23 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Surgery and 5 papers in Hematology. Recurrent topics in D. Johnston's work include Nausea and vomiting management (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Risks and Factors (3 papers). D. Johnston is often cited by papers focused on Nausea and vomiting management (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Risks and Factors (3 papers). D. Johnston collaborates with scholars based in Canada, United States and Singapore. D. Johnston's co-authors include Dongsheng Tu, Frances A. Shepherd, B. Findlay, Daniel de Castro, Andrea Bezjak, Michael Smylie, Tudor–Eliade Ciuleanu, P. Santabárbara, Sumitra Thongprasert and Vera Hirsh and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Oncogene.

In The Last Decade

D. Johnston

23 papers receiving 4.9k citations

Hit Papers

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer 2005 2026 2012 2019 2005 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
    2005 4.3k citations Frances A. Shepherd, José Rodrigues Pereira et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Johnston Canada 15 3.6k 3.5k 1.1k 664 463 23 5.1k
Jong Seok Lee South Korea 34 3.6k 1.0× 3.4k 0.9× 1.1k 1.0× 684 1.0× 593 1.3× 144 5.2k
Rogério Lilenbaum United States 33 5.5k 1.5× 5.6k 1.6× 2.1k 1.9× 1.2k 1.9× 473 1.0× 105 8.4k
Renato Martins United States 20 4.7k 1.3× 4.6k 1.3× 1.7k 1.6× 916 1.4× 363 0.8× 42 6.7k
P. Lianes Spain 28 2.7k 0.7× 2.7k 0.8× 1.2k 1.1× 496 0.7× 634 1.4× 77 4.3k
Orazio Caffo Italy 36 2.0k 0.6× 2.4k 0.7× 1.4k 1.2× 1.4k 2.0× 764 1.7× 230 4.8k
Allen Lee Cohn United States 38 2.4k 0.7× 4.7k 1.3× 1.5k 1.4× 1.3k 1.9× 875 1.9× 159 6.9k
Andréa Varga France 33 1.2k 0.3× 3.0k 0.8× 1.2k 1.1× 547 0.8× 911 2.0× 107 4.6k
Giacomo Cartenì Italy 27 1.4k 0.4× 1.7k 0.5× 648 0.6× 521 0.8× 864 1.9× 110 3.2k
Bruce J. Giantonio United States 31 1.6k 0.4× 3.4k 0.9× 1.3k 1.2× 748 1.1× 729 1.6× 124 5.0k
Christopher R. Garrett United States 25 2.4k 0.7× 2.8k 0.8× 1.4k 1.3× 780 1.2× 953 2.1× 50 5.3k

Countries citing papers authored by D. Johnston

Since Specialization
Citations

This map shows the geographic impact of D. Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Johnston more than expected).

Fields of papers citing papers by D. Johnston

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Johnston. The network helps show where D. Johnston may publish in the future.

Co-authorship network of co-authors of D. Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of D. Johnston. A scholar is included among the top collaborators of D. Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Johnston. D. Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banerji, Aleena, et al.. (2020). P150 LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY. Annals of Allergy Asthma & Immunology. 125(5). S21–S21. 1 indexed citations
2.
Riedl, Marc A., D. Johnston, William R. Lumry, et al.. (2020). P157 ATTACK-FREE STATUS DURING EXTENDED TREATMENT WITH LANADELUMAB FOR HEREDITARY ANGIOEDEMA: HELP OLE STUDY FINAL RESULTS. Annals of Allergy Asthma & Immunology. 125(5). S23–S23. 1 indexed citations
3.
Tachdjian, Raffi, et al.. (2018). LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES. Annals of Allergy Asthma & Immunology. 121(5). S38–S38. 1 indexed citations
4.
Cigler, Tessa, Harriet Richardson, Martin J. Yaffe, et al.. (2011). A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Research and Treatment. 126(2). 453–461. 34 indexed citations
5.
Cigler, Tessa, Dongsheng Tu, Martin J. Yaffe, et al.. (2009). A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Research and Treatment. 120(2). 427–435. 30 indexed citations
6.
Goss, Paul E., Harriet Richardson, Rowan T. Chlebowski, et al.. (2007). National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of Exemestane to Prevent Breast Cancer in Postmenopausal Women. Clinical Breast Cancer. 7(11). 895–900. 11 indexed citations
7.
Richardson, Harriet, D. Johnston, Joseph L. Pater, & Paul E. Goss. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Current Oncology. 14(3). 89–96. 35 indexed citations
8.
Shepherd, Frances A., José Rodrigues Pereira, Tudor–Eliade Ciuleanu, et al.. (2005). Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. New England Journal of Medicine. 353(2). 123–132. 4281 indexed citations breakdown →
9.
Latreille, Jean, Joseph L. Pater, D. Johnston, et al.. (1998). Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16(3). 1174–1178. 93 indexed citations
10.
Zee, Benny, Bernard F. Cole, George P. Browman, et al.. (1998). Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.. Journal of Clinical Oncology. 16(8). 2834–2839. 26 indexed citations
11.
Johnston, D., Dimitrios Hatzis, & Mary E. Sunday. (1998). Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma. Oncogene. 16(2). 167–177. 25 indexed citations
12.
Bergsagel, Daniel E., Séamus O’Reilly, Kirsten Wilson, et al.. (1998). Randomized trial of interferon-α maintenance in myeloma patients responding to melphalan and prednisone (MY-6). 6. 129–131. 1 indexed citations
13.
Pater, J, Benny Zee, Michael Palmer, D. Johnston, & David Osoba. (1997). Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30. Supportive Care in Cancer. 5(5). 410–413. 63 indexed citations
14.
Latreille, Jean, Francis Laberge, Paul Hoskins, et al.. (1995). Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Supportive Care in Cancer. 3(5). 307–312. 37 indexed citations
15.
Johnston, D., Jean Latreille, Francis Laberge, et al.. (1995). 1204 Preventing nausea and vomiting during days 2–7 following high dose cisplatin chemotherapy (HDCP). European Journal of Cancer. 31. S251–S251. 3 indexed citations
16.
Warr, David, Peter Venner, Joseph L. Pater, et al.. (1993). A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. European Journal of Cancer. 29(1). 33–36. 29 indexed citations
17.
Latreille, Jean, Francis Laberge, Paul Hoskins, et al.. (1993). Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy. European Journal of Cancer. 29. S208–S208. 5 indexed citations
18.
Browman, George P., Andrew R. Belch, Jamey Skillings, et al.. (1992). Modified adriamycin‐vincristine‐dexamethasone (m‐VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. British Journal of Haematology. 82(3). 555–559. 19 indexed citations
19.
Belch, Andrew R., Daniel E. Bergsagel, Kenneth S. Wilson, et al.. (1991). Effect of daily etidronate on the osteolysis of multiple myeloma.. Journal of Clinical Oncology. 9(8). 1397–1402. 145 indexed citations
20.
Bodey, Gerald P. & D. Johnston. (1971). Microbiological Evaluation of Protected Environments During Patient Occupancy. Applied Microbiology. 22(5). 828–836. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jong Seok Lee Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by P. Lianes Breakdown of academic impact, for papers by Orazio Caffo Breakdown of academic impact, for papers by Allen Lee Cohn Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Giacomo Cartenì Breakdown of academic impact, for papers by Bruce J. Giantonio Breakdown of academic impact, for papers by Christopher R. Garrett
Rankless by CCL
2026